Bioncotech enters clinical trial collaboration with Merck

10 December 2019
keytruda_merck_large

Spanish clinical-stage, immune-oncology company Bioncotech Therapeutics has entered into a Phase II clinical trial collaboration with a subsidiary of US pharma giant Merck & Co (NYSE: MRK), known as MSD outside the USA and Canada.

The collaboration will focus on the Phase II clinical evaluation of the combination of BO-112, Bioncotech’s lead program, and Keytruda (pembrolizumab), MSD’s anti-PD-1 therapy, in patients with select advanced-stage solid tumors with liver metastases. The trial will evaluate if the combination of stimulation of the innate immune system by direct intra-tumoral administration of BO-112, combined with systemic administration of pembrolizumab, shows safety and efficacy in patients with tumors that are poorly or only moderately responsive to monotherapy with an anti-PD1 agent.

“This collaboration is an important next step in the clinical development of BO-112 and the potential of the innate immune system and intra-tumoral route of administration to provide improved outcomes for cancer patients,” said Marisol Quintero, chief executive of Bioncotech, adding: “We consider MSD, with its extensive expertise in immune-oncology, as the ideal partner for Bioncotech to complete this study.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology